Urosphere acquires Urolead creating a center of excellence in preclinical urology.
Last December, the company has acquired Urolead, a company dedicated to uro-oncology and particularly to the development of Patient-Derived Xenografts (PDX) models for kidney, bladder and prostate cancers. Urolead’s expertise and PDX Biobank reinforces Urosphere’s activities providing a full package of specifically relevant models in oncology, from cells to PDXs.
“The acquisition of Urolead is an essential part of our development strategy aiming at offering a full package of drug discovery portfolio of services and capabilities in urology” said Dr. Philippe Lluel, CEO of Urosphere. “This is an exciting development for Urosphere as we continue to grow and meet the needs of our clients.”
The company broadens its portofolio of preclinical models and expands its offer from services, co-development of molecules to licensing of PDX models.
For further information, please do not hesitate to contact us email@example.com